FDA approves 1st drug for aggressive, noncancerous tumors

The FDA approved Ogsiveo (nirogacestat), the first drug indicated for locally aggressive, noncancerous tumors, on Nov. 27. 

Desmoid tumors are a rare subtype of soft tissue sarcomas that can cause pain, limited mobility and a decreased quality of life, the FDA said. Surgical removal has historically been used to treat these noncancerous tumors, but there is a high risk of it returning. 

In a clinical trial of 142 adult patients, study participants received either 150 milligrams of Ogsiveo or a placebo twice a day. Progression-free survival was found in 41% of those taking Ogsiveo and 8% in the placebo group. 

The FDA awarded the approval to SpringWorks Therapeutics. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars